• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer.社论：分析肿瘤免疫微环境及分子机制以揭示晚期非小细胞肺癌免疫治疗困境
Front Immunol. 2024 Apr 25;15:1415608. doi: 10.3389/fimmu.2024.1415608. eCollection 2024.
2
Lung cancer: potential targets for immunotherapy.肺癌：免疫治疗的潜在靶点。
Lancet Respir Med. 2013 Sep;1(7):551-63. doi: 10.1016/S2213-2600(13)70159-0. Epub 2013 Aug 23.
3
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.化疗诱导的非小细胞肺癌免疫调节：联合化疗免疫疗法的理论依据
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.
4
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
5
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
6
[Immunotherapy in non-small cell lung cancer patients: back to the future.].[非小细胞肺癌患者的免疫治疗：回归未来。]
Recenti Prog Med. 2019 Dec;110(12):587-593. doi: 10.1701/3278.32517.
7
Immunotherapy in the treatment of non-small cell lung cancer.免疫疗法在非小细胞肺癌治疗中的应用。
Klin Onkol. 2021 Spring;34(Supplementum 1):54-64. doi: 10.48095/ccko2021S54.
8
Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.针对 CD73 通路介导的 - 突变型非小细胞肺癌的免疫代谢靶向治疗：克服免疫耐药性的新希望。
Front Immunol. 2020 Jul 14;11:1479. doi: 10.3389/fimmu.2020.01479. eCollection 2020.
9
[Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].[非小细胞肺癌中免疫检查点抑制剂的预测生物标志物]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 12;43(2):87-91. doi: 10.3760/cma.j.issn.1001-0939.2020.02.004.
10
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.机器学习揭示了基于基因表达背景的非小细胞肺癌免疫治疗反应的 PD-L1 独立预测。
Eur J Cancer. 2020 Nov;140:76-85. doi: 10.1016/j.ejca.2020.09.015. Epub 2020 Oct 12.

本文引用的文献

1
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.癌症中免疫检查点阻断耐药的全景：潜在机制和克服耐药的当前策略。
Cancer Biol Ther. 2024 Dec 31;25(1):2308097. doi: 10.1080/15384047.2024.2308097. Epub 2024 Feb 2.
2
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗 NSCLC 患者血浆中可溶性 PD-1 和 PD-L1 的临床作用。
Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16.
3
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.治疗前可溶性 PD-L1 作为免疫检查点抑制剂治疗总生存期的预测因子：系统评价和荟萃分析。
Cancer Immunol Immunother. 2023 May;72(5):1061-1073. doi: 10.1007/s00262-022-03328-9. Epub 2022 Nov 16.
4
Immune Checkpoint Inhibitors in Cancer Therapy.癌症治疗中的免疫检查点抑制剂。
Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247.
5
Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer.新辅助免疫疗法有助于切除具有手术挑战性的肺鳞状细胞癌。
J Thorac Dis. 2021 Dec;13(12):6816-6826. doi: 10.21037/jtd-21-1195.

Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer.

作者信息

Roviello Giandomenico, Vascotto Ismaela Anna, Catalano Martina

机构信息

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

School of Human Health Sciences, University of Florence, Florence, Italy.

出版信息

Front Immunol. 2024 Apr 25;15:1415608. doi: 10.3389/fimmu.2024.1415608. eCollection 2024.

DOI:10.3389/fimmu.2024.1415608
PMID:38726009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11079269/
Abstract
摘要